Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E Balance Sheet Health
Financial Health criteria checks 3/6
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E has a total shareholder equity of EGP1.8B and total debt of EGP1.0B, which brings its debt-to-equity ratio to 57.8%. Its total assets and total liabilities are EGP3.2B and EGP1.5B respectively. Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E's EBIT is EGP477.4M making its interest coverage ratio 2.6. It has cash and short-term investments of EGP297.4M.
Key information
57.8%
Debt to equity ratio
ج.م1.03b
Debt
| Interest coverage ratio | 2.6x |
| Cash | ج.م297.45m |
| Equity | ج.م1.78b |
| Total liabilities | ج.م1.46b |
| Total assets | ج.م3.24b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: RMDA's short term assets (EGP2.1B) exceed its short term liabilities (EGP1.4B).
Long Term Liabilities: RMDA's short term assets (EGP2.1B) exceed its long term liabilities (EGP91.8M).
Debt to Equity History and Analysis
Debt Level: RMDA's net debt to equity ratio (41.1%) is considered high.
Reducing Debt: RMDA's debt to equity ratio has reduced from 128.8% to 57.8% over the past 5 years.
Debt Coverage: RMDA's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: RMDA's interest payments on its debt are not well covered by EBIT (2.6x coverage).